Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of ...

The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

U.K.-based AstraZeneca has scored the exclusive rights to develop and commercialize the pan-KRAS inhibitor, dubbed JAB-23E73, outside China. On Jacobio’s home territory, the Beijing-headquartered ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...

The pharma company claims ‘widespread defects’ in the construction of their Discovery Centre cost them millions ...

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a ...

Tuesday, December 30, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

FDA approves AstraZeneca and Daiichi's Enhertu combo for first-line HER2-positive breast cancer, while the EU clears Saphnelo self-injection for lupus.

The head of the pharmaceutical giant warns that Europe's decline in manufacturing innovative medicines is likely to accelerate as a result of the policies pursued by Donald Trump. According to Soriot, ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...